IPO Central

Gland Pharma IPO description – Gland Pharma is one of the fastest growing generic injectables-focused companies, selling its products primarily under a business to business (B2B) model in over 60 countries including the United States, Europe, Canada, Australia, India and the Rest of the world. The company was established in Hyderabad, India in 1978 and has expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. As of March 31, 2020, it had manufacturing capacity for finished formulations of approximately 755 million units per annum. As of March 31, 2020, the company and its partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products. 

Promoters of Gland Pharma – Fosun Pharma Industrial PTE Ltd and Shanghai Fosun Pharmaceutical (Group) Co Ltd